Loyal (Cellular Longevity)

What it is

Loyal is a biotech building drugs to extend healthspan and lifespan in companion dogs. Founder Celine Halioua argues that pet dogs are an ideal first market:

• They share the human environment, eat what their owners eat, develop similar age-related diseases.
• Trials can be much shorter and cheaper than human longevity trials.
• Owners are highly motivated to pay for proven healthspan extension.
• US regulatory framework (FDA Center for Veterinary Medicine) accepts “reasonable expectation of effectiveness” for lifespan extension as a conditional-approval path.

Lead programmes

• LOY-001 — injectable, targeting IGF-1 signalling in large-breed dogs (whose size correlates with shorter lifespan).
• LOY-002 — oral, for general healthspan in older dogs of all sizes.
• LOY-003 — oral, targeting senescent cells.

LOY-002 received the FDA-CVM’s conditional approval pathway as a “reasonable expectation of effectiveness” for lifespan in 2024 — a first of its kind.

Why it matters for humans

• Validates the drug-development pathway and regulatory framework for geroscience interventions.
• Companion-dog trials can read out in years rather than decades, accelerating learning.
• Successful canine programmes may pull human equivalents into trials.

Related entries

Insulin/IGF-1 signalling, Matt Kaeberlein, Senolytics.